undamentalytics Newsletter
Sign in

Elanco Animal Health Inc income statement

In fiscal 2025, Elanco Animal Health Inc reported revenue of $4.71bn, up 6.2% on the year before and net income of −$232m, or −$0.47 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue2,9142,8893,0673,0713,2734,7644,4114,4174,4394,7155,020
Cost of revenue1,4091,4941,5741,4701,6672,1321,9131,9312,0032,1222,241
Gross profit1,5051,3951,4931,6011,6062,6322,4982,4862,4362,5932,779
Research and development266252247270329369321327344368371
Selling, general and administrative7857807357609971,4031,2651,2851,3141,4301,519
Interest expense003079150236241277———
Income before tax−22−23311478−677−571−72−1,195488−224−166
Income tax26782810−103−88636150833
Net income−48−3118768−574−483−78−1,231338−232−199
Diluted EPS−$0.16−$1.06$0.28$0.18−$1.30−$0.99−$0.16−$2.50$0.68−$0.47−$0.40
Diluted shares (average)293m293m314m370m441m487m488m492m497m496m500m

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ELAN vs JAZZELAN vs OGNAMRX vs ELAN

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Elanco Animal Health Inc's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Elanco Animal Health Inc.